Organon & Co
NYSE:OGN
Organon & Co
NYSE:OGN
Price:
6.335
USD
-1.02%
Market Cap:
$1.6B
Relative Value
The Relative Value of one
OGN
stock under the Base Case scenario is
45.288
USD.
Compared to the current market price of 6.335 USD,
Organon & Co
is
Undervalued by 86%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OGN
Relative Value
Base Case
45.288
USD
Undervaluation 86%
Multiples Across Competitors
OGN Competitors Multiples
Organon & Co Competitors
Organon & Co Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Organon & Co
NYSE:OGN
|
1.6B USD | 0.3 | 8.8 | 5.7 | 7.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
924.1B USD | 14.1 | 44.6 | 30.1 | 32.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.8B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
253.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP | 5.1 | 29.3 | 16.2 | 22.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.8B CHF | 5.3 | 21.4 | 13.2 | 17 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.3B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
